)
PeptiDream (4587) investor relations material
PeptiDream Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Nine-month revenue rose 15.3% YoY to ¥14,820 million; operating loss narrowed to ¥2,867 million and net loss attributable to owners narrowed to ¥2,363 million.
Full-year 2026 guidance remains unchanged, with revenue of ¥32,000 million and operating profit of ¥4,600 million; second-half upfront and R&D milestone revenue is expected to support full-year operating profit.
Financial highlights
Revenue increased by ¥1,963 million YoY to ¥14,820 million; gross profit rose to ¥6,960 million from ¥4,835 million.
Operating loss narrowed by ¥1,191 million YoY to ¥2,867 million; core operating loss narrowed by ¥1,175 million to ¥2,804 million.
Loss before tax was ¥3,154 million versus ¥4,340 million YoY; net loss was ¥2,363 million versus ¥3,217 million, and basic EPS was -¥18.35 versus -¥24.88.
Finance costs were ¥429 million, versus finance income of ¥146 million; income tax benefit was ¥791 million.
Outlook and guidance
FY2026 forecast: revenue ¥32,000 million, core operating profit ¥4,600 million, operating profit ¥4,600 million, profit before tax ¥4,300 million and net profit ¥3,000 million; guidance unchanged.
Full-year operating profit is expected to be supported by upfront payments under drug discovery and development agreements and R&D milestone revenue in H2.
FY2026 forecasts include capital expenditures of ¥5,449 million, depreciation of ¥1,922 million, R&D expenses of ¥6,445 million and period-end headcount of 810.
- Revenue grew, but profit fell; FY2024 guidance targets a sharp rebound.4587
Q4 2023 - Six new clinical programs and 30% PET revenue growth drive improved H1 2026 results.4587
Q2 2026 - Clinical pipeline expansion, new modalities, and AI-driven efficiency fuel growth and innovation.4587
Jefferies Global Healthcare Conference 2026 - Q1 2026 revenue rose 12.6% and net loss narrowed, with strong FY2026 growth forecast.4587
Q1 2026 - FY2025 revenue fell 60% to ¥18.5B; FY2026 targets ¥32B and 6–12 new clinical programs.4587
Q4 2025 - Radiopharmaceutical and peptide pipeline advances, plus facility investments, fuel strong growth.4587
Status Update - Late-stage radiopharma pipeline and AI-driven discovery fuel growth and global partnerships.4587
Investor Day 2024 - Record H1 2024 profit and revenue driven by Drug Discovery and Novartis deal expansion.4587
Q2 2024 - FY2024 saw record revenue and profit growth, robust pipeline, and strong guidance for FY2025.4587
Q4 2024
)
)
)
)
)
)
)
)